Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
HIV persists in the central nervous system (CNS), and a subset of PWH develop neurocognitive issues despite virally suppression. With a diverse set of infected cells comprising the CNS reservoir, along with the impact of both acute and chronic infection on local inflammation and blood brain barrier integrity, the CNS presents an important and unique…
This talk will highlight the burden and spectrum of post-tuberculosis disease, focusing on the complexities of clinical presentation and pitfalls in assessment. We will give an overview of pathogenesis, and an update of recent work in post-tuberculosis lung disease (PTLD). We will highlight important knowledge gaps in the field, and will discuss ongoing work and…
Long-acting injectables (LAI) represents one of the most significant advances in antiretroviral therapy in recent years, offering durable suppression for PLWH who find daily oral medications challenging. Confirmed virological failure (CVF) is a low-incidence (1.4% over 152 weeks) but high-consequence event, with almost all developing drug-resistant mutations. This is in contrast to daily oral INSTI-based…
Over the last 40 years, remarkable achievements have been recorded in the HIV response, with service delivery models that have increased access to HIV testing, expansion of the HIV prevention toolbox, availability of newer and less toxic antiretroviral therapy resulting in fewer people acquiring HIV in 2023 than at any point since the late 1980’s…
The objectives of this talk are to: (1) define different patterns of HIV rebound (i.e., categories of post-ART control), (2) review examples of effective immune responses against HIV, focusing on immune mechanisms that have been implicated in post-ART control, and (3) discuss lessons learned about immune responses to rebound from recent ATI trials, including the…
In 2025, late diagnosis of HIV in children continues to be a significant global concern, with many presenting with advanced HIV disease (AHD). This issue contributes to a considerable number of hospital admissions, particularly among infants, due to acute conditions such as pneumonia, sepsis, and diarrhea. These acute illnesses are frequently accompanied by important by…
HIV-1 persists in a mostly latent state within blood and tissues during suppressive ART. Proviral integration sites may play a critical role in the establishment and maintenance of this latent reservoir. Understanding the landscape of proviral integration is essential for deciphering the mechanisms behind HIV-1 latency and reactivation. Recent studies have shed light on the…
Disentangling the unique impacts of aging and reproductive aging through menopause may identify novel features of the pathogenesis of HIV that will inform strategies to manage longterm complications and achieve an HIV cure. Early data indicate that menopause and declining levels of estradiol are associated with increased inflammation and changes in HIV viral dynamics. Further…
Long-acting injectable formulations are revolutionizing HIV treatment and prevention and have similar potential to improve the treatment and prevention of tuberculosis, including simpler, shorter regimens and expanded treatment options. This presentation will describe how long-acting injectable formulations could address important obstacles to ending the world’s oldest pandemic, review recent progress in the development of long-acting…
In the past 12 years, 6.2 million individuals globally have been prescribed PrEP since its initial approval by the US FDA. The majority of these prescriptions, 1.4 million, have been issued in the past two years. However, oral PrEP’s effectiveness is contingent on high adherence, posing challenges for certain high-risk groups. Research indicates that long-acting…